Ray McDermott
Impact in
- Oncology top 0.5%
- Cancer Immunotherapy and Biomarkers
- Colorectal Cancer Treatments and Studies
- Pathology and Forensic Medicine top 0.5%
- Genetic factors in colorectal cancer
Papers in
- Oncology 63
- Colorectal Cancer Treatments and Studies 18
- Cancer Immunotherapy and Biomarkers 13
- PARP inhibition in cancer therapy 9
-
- Prostate Cancer Treatment and Research 29
- Lung Cancer Treatments and Mutations 14
- Prostate Cancer Diagnosis and Treatment 9
- Co-authors
- Scott Kopetz (8 shared papers)Michael J. Overman (8 shared papers)Sara Lonardi (8 shared papers)Thierry André (8 shared papers)Andrew Hill (6 shared papers)Rebecca A. Moss (6 shared papers)Z. Alexander Cao (5 shared papers)Heinz‐Josef Lenz (6 shared papers)
- Journals
- Annals of Oncology (33 papers)Journal of Clinical Oncology (14 papers)Cancers (5 papers)Cancer Research (3 papers)HPB (3 papers)
- Partner nations
- IrelandUnited StatesAustralia
In The Last Decade
Ray McDermott
144 papers receiving 6.5k citations
Ray McDermott's Hit Papers
Peers
Comparison fields: 5 of 137
- Oncology 3.4k
- Pathology and Forensic Medicine 1.3k
- Cancer Research 1.0k
- Immunology 795
- Pulmonary and Respiratory Medicine 1.1k
Countries citing papers authored by Ray McDermott
This map shows the geographic impact of Ray McDermott's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ray McDermott with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ray McDermott more than expected).
Fields of papers citing papers by Ray McDermott
This network shows the impact of papers produced by Ray McDermott. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ray McDermott. The network helps show where Ray McDermott may publish in the future.
Co-authors
The 25 scholars most cited alongside Ray McDermott, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 150 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study Hit paper breakdown → | 2017 | 2047 |
| 2 | Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair–Deficient/Microsatellite Instability–High Metastatic Colorectal Cancer Hit paper breakdown → | 2018 | 1478 |
| 3 | 2012 | 398 | |
| 4 | Nivolumab plus low-dose ipilimumab in previously treated patients with microsatellite instability-high/mismatch repair-deficient metastatic colorectal cancer: 4-year follow-up from CheckMate 142 Hit paper breakdown → | 2022 | 167 |
| 5 | 2013 | 139 | |
| 6 | 2013 | 114 | |
| 7 | 1999 | 102 | |
| 8 | 2005 | 100 | |
| 9 | Efficacy and safety of larotrectinib in patients with TRK fusion-positive thyroid carcinoma | 2022 | 96 |
| 10 | 2014 | 87 | |
| 11 | 2016 | 81 | |
| 12 | 2011 | 81 | |
| 13 | 2000 | 78 | |
| 14 | 2019 | 70 | |
| 15 | 2002 | 63 | |
| 16 | 2019 | 57 | |
| 17 | 2017 | 56 | |
| 18 | 2010 | 54 | |
| 19 | 2000 | 52 | |
| 20 | 2014 | 51 |
About Ray McDermott
Ray McDermott is a scholar working on Oncology, Pulmonary and Respiratory Medicine, Surgery, Molecular Biology and Cancer Research, having authored 150 papers that have together received 6.6k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (29 papers), Colorectal Cancer Treatments and Studies (18 papers), Lung Cancer Treatments and Mutations (14 papers), Cancer Immunotherapy and Biomarkers (13 papers), Radiopharmaceutical Chemistry and Applications (12 papers), Cancer Genomics and Diagnostics (9 papers), Prostate Cancer Diagnosis and Treatment (9 papers) and PARP inhibition in cancer therapy (9 papers). The work is most often cited by research in Oncology (3.4k citations), Pathology and Forensic Medicine (1.3k citations), Cancer Research (1.0k citations), Immunology (795 citations) and Pulmonary and Respiratory Medicine (1.1k citations). Ray McDermott has collaborated with scholars based in Ireland, United States and Australia. Frequent co-authors include Scott Kopetz, Michael J. Overman, Sara Lonardi, Thierry André, Andrew Hill, Rebecca A. Moss, Z. Alexander Cao, Heinz‐Josef Lenz, Jean-Marie Ledeine and Michael A. Morse. Their work appears in journals such as Annals of Oncology, Journal of Clinical Oncology, Cancers, Cancer Research and HPB.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.